VTV.vn - Pfizer Vietnam, in collaboration with Vietnam Cancer Association and Vietnam Cancer Immunotherapy Association, ...

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III ...

Baseline tumor-infiltrating lymphocytes and positive nodes can help identify women with TMBC at high risk for relapse despite ...

Health experts discuss advanced biologic therapies in breast cancer treatment at a recent symposium in Hà Nội.

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

The breast cancer treatment market is rapidly growing, driven by advances in technology, personalized therapies and early diagnosis efforts.

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA -mutated, ...

Market OverviewBreast cancer remains one of the most prevalent forms of cancer worldwide, affecting millions of individuals ...

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.